Amotiv Limited - Asset Resilience Ratio

Latest as of December 2025: 4.12%

Amotiv Limited (AOV) has an Asset Resilience Ratio of 4.12% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CA$43.13 Million
≈ $31.20 Million USD Cash + Short-term Investments

Total Assets

CA$1.05 Billion
≈ $756.88 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2014–2025)

This chart shows how Amotiv Limited's Asset Resilience Ratio has changed over time. Check Amotiv Limited PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Amotiv Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Amotiv Limited (AOV) market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CA$5.35 Million 0.51%
Short-term Investments CA$37.78 Million 3.61%
Total Liquid Assets CA$43.13 Million 4.12%

Asset Resilience Insights

  • Limited Liquidity: Amotiv Limited maintains only 4.12% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Amotiv Limited Industry Peers by Asset Resilience Ratio

Compare Amotiv Limited's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Galderma Group N
SW:GALD
Drug Manufacturers - Specialty & Generic 3.56%
Viatris Inc
NASDAQ:VTRS
Drug Manufacturers - Specialty & Generic 1.62%
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
Drug Manufacturers - Specialty & Generic 0.20%
Changchun High & New Technology Industries Group Inc
SHE:000661
Drug Manufacturers - Specialty & Generic 5.50%
Beijing Winsunny Pharmaceutical CO.LTD
SHG:601089
Drug Manufacturers - Specialty & Generic 10.89%
Renhe Pharmacy Co Ltd
SHE:000650
Drug Manufacturers - Specialty & Generic 37.54%
Shanghai Jiaoda Onlly Co Ltd
SHG:600530
Drug Manufacturers - Specialty & Generic 0.82%
Hainan Shuangcheng Pharmaceut
SHE:002693
Drug Manufacturers - Specialty & Generic 1.03%

Annual Asset Resilience Ratio for Amotiv Limited (2014–2025)

The table below shows the annual Asset Resilience Ratio data for Amotiv Limited.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 4.12% CA$43.13 Million
≈ $31.20 Million
CA$1.05 Billion
≈ $756.88 Million
-5.02pp
2024-12-31 9.14% CA$88.13 Million
≈ $63.75 Million
CA$963.80 Million
≈ $697.20 Million
-2.67pp
2023-12-31 11.82% CA$111.73 Million
≈ $80.83 Million
CA$945.49 Million
≈ $683.96 Million
+0.46pp
2022-12-31 11.36% CA$119.84 Million
≈ $86.69 Million
CA$1.05 Billion
≈ $763.05 Million
+2.68pp
2021-12-31 8.68% CA$86.06 Million
≈ $62.26 Million
CA$991.89 Million
≈ $717.52 Million
-9.05pp
2020-12-31 17.73% CA$184.33 Million
≈ $133.34 Million
CA$1.04 Billion
≈ $752.09 Million
-2.70pp
2019-12-31 20.43% CA$266.69 Million
≈ $192.92 Million
CA$1.31 Billion
≈ $944.24 Million
-23.21pp
2018-12-31 43.64% CA$459.03 Million
≈ $332.06 Million
CA$1.05 Billion
≈ $760.88 Million
+14.12pp
2017-12-31 29.52% CA$296.93 Million
≈ $214.79 Million
CA$1.01 Billion
≈ $727.71 Million
-50.00pp
2016-12-31 79.52% CA$787.84 Million
≈ $569.91 Million
CA$990.77 Million
≈ $716.71 Million
+39.87pp
2015-12-31 39.65% CA$257.31 Million
≈ $186.14 Million
CA$648.99 Million
≈ $469.47 Million
+10.16pp
2014-12-31 29.49% CA$143.50 Million
≈ $103.81 Million
CA$486.61 Million
≈ $352.01 Million
--
pp = percentage points

About Amotiv Limited

TO:AOV Canada Drug Manufacturers - Specialty & Generic
Market Cap
$720.14 Million
CA$995.51 Million CAD
Market Cap Rank
#11373 Global
#333 in Canada
Share Price
CA$9.82
Change (1 day)
+1.34%
52-Week Range
CA$5.75 - CA$10.07
All Time High
CA$10.90
About

Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting;… Read more